LX1001

Asset

AAVrh10 gene therapy expressing human APOE2 to convert CSF phenotype in APOE4 homozygotes

Stage: Phase 1
Modality: Gene therapy
Target: Lipid and ceramide metabolism; 2
Indications: 2
Trials: 1
Developer

Indications

2

Alzheimer's disease
Phase 1, Completed, NCT03634007, clinicaltrials.gov, 7 Oct 2026
Early-onset Alzheimer's disease
Phase 1, Completed, NCT03634007, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains3
Owner and partners3
Trials2
Evidence for its targets3
Competitors12
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 2 sources